PTH and hypoparathyroidism: The trial is a multicenter, randomized, double-blind, placebo-controlled (4-week screening period, 26-week treatment period (blinded)) study, which is currently in an open-label extension of 156 weeks, designed to evaluate the safety and efficacy of TransCon PTH administered subcutaneously once daily in adults with hypoparathyroidism.